Pharmacokinetics, pharmacodynamics, and safety of administering pegylated recombinant megakaryocyte growth and development factor to newborn rhesus monkeys

被引：0
|
作者：
Sola, MC
Christensen, RD
Hutson, AD
Tarantal, AF
机构：
[1] Univ Florida, Gainesville, FL USA
[2] Calif Reg Primate Res Ctr, Davis, CA USA
来源：
PEDIATRIC RESEARCH | 1999年 / 45卷 / 04期
关键词：
D O I：
10.1203/00006450-199904020-01575
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
1558
引用
收藏
页码：265A / 265A
页数：1
相关论文
共 50 条
  • [21] The pharmacokinetics, pharmacodynamics and safety of pegylated recombinant human growth hormone after single subcutaneous injections in adult male patients with growth hormone deficiency
    Abs, Roger
    Didier, Eric
    Boonen, Ann
    Kantaridis, Constantino
    Weissgerber, Georges
    Harris, Philip
    HORMONE RESEARCH, 2006, 65 : 148 - 148
  • [22] Decreased prothrombotic effects of pegylated recombinant human megakaryocyte growth and development factor in thrombocytopenic state in a rat thrombosis model
    Nishiyama, U
    Kuwaki, T
    Akahori, H
    Kato, T
    Ikeda, Y
    Miyazaki, H
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (02) : 355 - 360
  • [23] Effects of pegylated recombinant human megakaryocyte growth and development factor on thrombocytopenia induced by a new myelosuppressive chemotherapy regimen in mice
    Akahori, H
    Shibuya, K
    Ozai, M
    Ida, M
    Kabaya, K
    Kato, T
    Miyazaki, H
    STEM CELLS, 1996, 14 (06) : 678 - 689
  • [24] Marked improvement of thrombocytopenia in a murine model of idiopathic thrombocytopenic purpura by pegylated recombinant human megakaryocyte growth and development factor
    Shibuya, K
    Kuwaki, T
    Tahara, E
    Yuki, C
    Akahori, H
    Kato, T
    Miyazaki, H
    EXPERIMENTAL HEMATOLOGY, 2002, 30 (10) : 1185 - 1192
  • [25] Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer
    Basser, RL
    Rasko, JEJ
    Clarke, K
    Cebon, J
    Green, MD
    Hussein, S
    Alt, C
    Menchaca, D
    Tomita, D
    Marty, J
    Fox, RM
    Begley, CG
    LANCET, 1996, 348 (9037): : 1279 - 1281
  • [26] Treatment of thrombocytopenia in chimpanzees infected with human immunodeficiency virus by pegylated recombinant human megakaryocyte growth and development factor.
    Harker, LA
    Marzec, UM
    Novembre, F
    Sundell, IB
    Waller, EK
    Karpatkin, S
    McClure, HM
    Kelly, AB
    Stead, RB
    BLOOD, 1997, 90 (10) : 754 - 754
  • [27] Pegylated recombinant human megakaryocyte growth and development factor stimulates mobilization of hematopoietic progenitor cells into the peripheral blood in mice
    Torii, Y
    Nitta, Y
    Ida, M
    Kuwaki, T
    Akahori, H
    Kato, T
    Miyazaki, H
    EXPERIMENTAL HEMATOLOGY, 1997, 25 (08) : 288 - 288
  • [28] Erratum: Improvement of thrombocytopenia following bone marrow transplantation by pegylated recombinant human megakaryocyte growth and development factor in mice
    K Kabaya
    K Shibuya
    Y Torii
    Y Nitta
    M Ida
    H Akahori
    T Kato
    M Kusaka
    H Miyazaki
    Bone Marrow Transplantation, 1997, 20 : 619 - 620
  • [29] Systemic effects of pegylated recombinant human megakaryocyte growth and development factor in combination with recombinant murine granulocyte colony-stimulating factor in a murine model of myelosuppression
    Coleman, D
    Fairchild, D
    Schindler-Horvat, J
    Munyakazi, L
    Neumann, TAK
    TOXICOLOGICAL SCIENCES, 1998, 45 (01) : 77 - 87
  • [30] Pharmacodynamics of pegylated megakaryocyte growth & development factor from a phase I study: Effects of platelet count on serum levels & clearance.
    deBoer, R
    Fox, S
    Hopkins, W
    Casper, L
    Cheung, E
    Roskos, L
    Basser, R
    Cebon, J
    EXPERIMENTAL HEMATOLOGY, 1996, 24 (09) : 744 - 744
12345